MARKET

SCNLF

SCNLF

Scancell Holdings Plc London
OTCPK
0.313
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
0.313
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.313
52 WEEK LOW
0.119
MARKET CAP
325.24M
P/E (TTM)
-44.7714
1D
5D
1M
3M
1Y
5Y
1D
Scancell Wins FDA Fast Track for Melanoma Vaccine as Phase 2 Data Strengthen
TipRanks · 04/28 06:09
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
Barchart · 04/28 01:00
Scancell Taps Veteran Biotech Financier as Interim CFO Amid iSCIB1+ Push
TipRanks · 04/02 06:16
Scancell Holdings Charts Risky but Promising Phase III Path
TipRanks · 01/31 00:23
Scancell Holdings plc GAAP EPS of -£0.64p
Seeking Alpha · 01/29 15:31
Scancell Secures FDA Green Light for Phase 3 Melanoma Trial as Pipeline and Cash Runway Advance
TipRanks · 01/29 07:25
Interim Results for the six months ended 31 October 2025
Barchart · 01/29 01:00
Scancell Wins FDA Nod for Phase 3 Melanoma Trial of iSCIB1+ After Strong Phase 2 Data
TipRanks · 01/26 07:20
More
About SCNLF
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

Webull offers Scancell Holdings Plc stock information, including OTCPK: SCNLF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNLF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNLF stock methods without spending real money on the virtual paper trading platform.